Ernexa Therapeutics (ERNA) Competitors $1.62 -0.01 (-0.31%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. ATHE, ATNM, TELO, ADVM, LTRN, PRLD, ALGS, BRNS, NBRV, and SLGLShould you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Alterity Therapeutics (ATHE), Actinium Pharmaceuticals (ATNM), Telomir Pharmaceuticals (TELO), Adverum Biotechnologies (ADVM), Lantern Pharma (LTRN), Prelude Therapeutics (PRLD), Aligos Therapeutics (ALGS), Barinthus Biotherapeutics (BRNS), Nabriva Therapeutics (NBRV), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Ernexa Therapeutics vs. Its Competitors Alterity Therapeutics Actinium Pharmaceuticals Telomir Pharmaceuticals Adverum Biotechnologies Lantern Pharma Prelude Therapeutics Aligos Therapeutics Barinthus Biotherapeutics Nabriva Therapeutics Sol-Gel Technologies Ernexa Therapeutics (NASDAQ:ERNA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership. Is ERNA or ATHE more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -726.54% Alterity Therapeutics N/A N/A N/A Does the media refer more to ERNA or ATHE? In the previous week, Ernexa Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.87 beat Ernexa Therapeutics' score of 0.65 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Ernexa Therapeutics Positive Alterity Therapeutics Very Positive Which has stronger valuation & earnings, ERNA or ATHE? Alterity Therapeutics has lower revenue, but higher earnings than Ernexa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K20.49-$44.54M-$8.31-0.19Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Which has more volatility and risk, ERNA or ATHE? Ernexa Therapeutics has a beta of 5.42, suggesting that its share price is 442% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ERNA or ATHE? 70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend ERNA or ATHE? Alterity Therapeutics has a consensus price target of $12.00, indicating a potential upside of 130.77%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryAlterity Therapeutics beats Ernexa Therapeutics on 8 of the 12 factors compared between the two stocks. Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.89M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.1922.0530.2925.74Price / Sales20.49742.42470.66115.79Price / CashN/A184.4138.2159.48Price / Book3.234.838.846.15Net Income-$44.54M$31.61M$3.25B$265.06M7 Day Performance-5.00%4.55%3.72%2.60%1 Month Performance-15.89%5.69%5.86%2.83%1 Year Performance-93.78%12.71%30.23%25.58% Ernexa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAErnexa Therapeutics0.6482 of 5 stars$1.62-0.3%N/A-93.8%$11.89M$580K-0.1910Earnings ReportShort Interest ↑ATHEAlterity Therapeutics3.1476 of 5 stars$5.30-0.4%$12.00+126.4%+284.6%$47.17MN/A0.0010ATNMActinium Pharmaceuticals2.9582 of 5 stars$1.51+2.7%$4.50+198.0%-15.6%$47.11MN/A-1.0930News CoveragePositive NewsShort Interest ↓Analyst RevisionTELOTelomir Pharmaceuticals2.8977 of 5 stars$1.55-1.9%$15.00+867.7%-58.8%$47.03MN/A0.001Earnings ReportGap DownADVMAdverum Biotechnologies3.9366 of 5 stars$2.47+10.3%$23.80+863.6%-57.1%$46.79M$1M0.00190News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionLTRNLantern Pharma2.7136 of 5 stars$4.45+2.8%$25.00+461.8%+16.0%$46.70MN/A0.0020Earnings ReportGap UpPRLDPrelude Therapeutics3.0744 of 5 stars$0.84+1.3%$4.50+437.0%-81.7%$46.69M$7M0.00120News CoverageEarnings ReportALGSAligos Therapeutics4.4581 of 5 stars$7.43-1.8%$70.00+842.1%-38.4%$46.28M$3.94M0.0090News CoverageBRNSBarinthus Biotherapeutics2.4448 of 5 stars$1.22+7.0%$6.25+412.3%-4.1%$45.99M$14.97M0.00107Negative NewsShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070SLGLSol-Gel Technologies2.9576 of 5 stars$15.25-5.9%$40.00+162.3%+281.3%$45.14M$11.54M0.0050Positive NewsEarnings Report Related Companies and Tools Related Companies ATHE Alternatives ATNM Alternatives TELO Alternatives ADVM Alternatives LTRN Alternatives PRLD Alternatives ALGS Alternatives BRNS Alternatives NBRV Alternatives SLGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access